Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.
Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O. Cabagnols X, et al. Among authors: viallard jf. Leukemia. 2015 Jan;29(1):249-52. doi: 10.1038/leu.2014.270. Epub 2014 Sep 12. Leukemia. 2015. PMID: 25212275 No abstract available.
Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J, Viallard JF, Keddad K, Smith J, Wilde P, Kiladjian JJ; FOX study investigators. Rey J, et al. Among authors: viallard jf. Eur J Haematol. 2014 Feb;92(2):127-36. doi: 10.1111/ejh.12210. Epub 2013 Nov 25. Eur J Haematol. 2014. PMID: 24118452 Free PMC article. Clinical Trial.
Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.
Mansier O, Luque Paz D, Ianotto JC, Le Bris Y, Chauveau A, Boyer F, Conejero C, Fitoussi O, Riou J, Adiko D, Touati M, Chauzeix J, Viallard JF, Béné MC, Giraudier S, Ugo V, Lippert E. Mansier O, et al. Among authors: viallard jf. Am J Hematol. 2018 Aug;93(4):E84-E86. doi: 10.1002/ajh.25014. Epub 2018 Jan 12. Am J Hematol. 2018. PMID: 29266414 Free article. No abstract available.
The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation.
Mansier O, Prouzet-Mauléon V, Jégou G, Barroso K, Raymundo DP, Chauveau A, Dumas PY, Lagarde V, Turcq B, Pasquet JM, Viallard JF, James C, Praloran V, Voutetakis K, Chatziioannou A, Mahon FX, Chevet E, Lippert E. Mansier O, et al. Among authors: viallard jf. Cancers (Basel). 2019 Dec 2;11(12):1921. doi: 10.3390/cancers11121921. Cancers (Basel). 2019. PMID: 31810292 Free PMC article.
Reversible myelofibrosis induced by tuberculosis.
Viallard JF, Parrens M, Boiron JM, Texier J, Mercie P, Pellegrin JL. Viallard JF, et al. Clin Infect Dis. 2002 Jun 15;34(12):1641-3. doi: 10.1086/340524. Epub 2002 May 16. Clin Infect Dis. 2002. PMID: 12032901
Looking for somatic mutations in UBA1 in patients with chronic myelomonocytic leukemia associated with systemic inflammation and autoimmune diseases.
Dupuy H, Dussiau C, Bidet A, Sauvezie M, De-Grande AC, Decombe J, Rivière É, Forcade E, Bonnet F, Dumas PY, Duffau P, Pigneux A, Viallard JF, Lazaro E, Dimicoli-Salazar S. Dupuy H, et al. Among authors: viallard jf. Leuk Lymphoma. 2022 Jan;63(1):250-252. doi: 10.1080/10428194.2021.1973674. Epub 2021 Sep 3. Leuk Lymphoma. 2022. PMID: 34474632 No abstract available.
389 results